Breast Cancer Genetic Testing Criteria

Criteria for Mainstream Medicare Funded Testing

- MBS Item # 73296 Personal and Family History
 - Breast cancer with a Manchester score ≥15 or CanRisk score ≥10%
- MBS Item # 73295 To determine PARP inhibitor Eligibility*
 - Early-stage HER2 negative breast cancer, specifically:
 - Patients having neoadjuvant chemotherapy OR
 - Patients having adjuvant chemotherapy with
 - triple negative breast cancer and a high-risk factor
 (primary tumour >20mm OR lymph node involvement)
 - o hormone positive breast cancer AND ≥4 lymph nodes involved
 - Metastatic HER2 negative breast cancer, following:
 - Chemotherapy (either neoadjuvant, adjuvant or palliative setting) AND
 - Progression on endocrine therapy for hormone positive breast cancer
 *Please see the PBS for detailed eligibility criteria

If not eligible on above criteria, do <u>not</u> offer mainstream genetic testing. Consider referral to the Adult Genetics Unit for the following patients:

Genetic testing <u>will</u> be offered by the <u>Adult Genetics Unit</u> for the following patients:

- Male breast cancer
- Triple negative breast cancer (not meeting the above criteria)
- Invasive breast cancer diagnosed ≤40 years of age
- Bilateral breast cancer with the first cancer diagnosed ≤50 years of age
- Breast cancer with Ashkenazi Jewish ancestry

Genetic testing <u>may</u> be offered by the <u>Adult Genetics Unit</u> for the following patients:

- Breast cancer diagnosed <50 years of age with a small and/or male dominant family structure (limited female relatives)
- Bilateral lobular breast cancer

Adult Genetics Unit

Tel: (08) 7074 2697 Fax: (08) 8429 6112

Email: adultgenetics@sa.gov.au





OFFICIAL

Breast Cancer Mainstream Genetic Testing Checklist

		Patient name: DOB: UR: EMR Visit: (or patient label)					
	Pati	ent's family history taken and documented					
	Provide patient with genetic testing information leaflets						
	Discuss genetic testing with patient						
	Complete Consent to Genetic Testing form						
	- -	vide patient with completed SA Pathology reques 4mL blood in EDTA tube Cc: Responsible Consultant Cc: Adult Genetics Unit, Royal Adelaide Hospital Include requested time frame for treatment for genetic testing results (chemotherapy complete)	cused				
	Place a copy of consent form and this checklist in patient notes (Paper or scan to EMR)						
	Ensure patient follow-up appointment in 3 months to discuss results (date of appointment / /)						
MC) Sig	nature: Date	//				





MANCHESTER Scoring System with pathology adjustment (2017)

DATE	NAME	DOB	UR

Cancer (age at Dx) count invasive breast cancer & DCIS; do not count LCIS	Score		nt's score gy adjust Br+Ov	Relatives' scores pathology adjust Ov only
Female Breast Ca <30	11			
Female Breast Ca 30-39	8			
Female Breast Ca 40-49	6			
Female Breast Ca 50-59	4			
Female Breast Ca >59	2			
Male Breast Ca <60	13			
Male Breast Ca >59	10			
Epithelial ovarian (any grade) <60	13			
Epithelial ovarian Ca (any grade) >59	10			
Pancreatic Ca	1			
Prostate Ca <60	2			
Prostate Ca >59	1			
Adjust for breast cancer histology (for index	case only)			
DCIS only	-2			no adjustment needed
Lobular histology	-2			no adjustment needed
Adjust for grade and receptors (for index case with ductal cancer or DCIS only)				
Grade 3	2			no adjustment needed
Grade 2	0			no adjustment needed
Grade 1	-2			no adjustment needed
ER positive	-1			no adjustment needed
ER negative	1			no adjustment needed
Triple negative	4			no adjustment needed
HER2 positive	-6			no adjustment needed
Ovarian cancer pathology adjustment (for all	cases in th	e family	y)	
High grade serous <60	2			
Do not score mucinous, germ cell, borderline	score 0			
Adjustment for lack of family history (adjust once only)				
Adopted or no knowledge of blood relatives	4			no adjustment needed
	Total	A=		B=
Manchester Score (add A+B)			CanRisk (if done)

Scoring BrCa: Bilateral breast cancer is counted separately (i.e. score each breast cancer); DCIS is included as invasive breast cancer (all cases); lobular breast cancer is included as invasive breast cancer; LCIS is <u>not</u> counted.

Histology: For DCIS and invasive ductal breast cancer adjust for histology, grade and/or receptors (where available) for the index case only (e.g. grade 3 triple negative = +2 for G3 and +4 for TN). Grade and/or receptor

adjustment is **not** made for invasive lobular breast cancer.

Scoring OvCa: Only score epithelial ovarian cancer; do <u>not</u> score mucinous, germ cell or borderline ovarian tumours.

In the case of bilinear family history, the highest score from either side is used (do not add together).

Reference: Evans et al. J Med Genet 2017 54(10):674-681

OFFICIAL

This page is intentionally blank

Government of South Australia SA Health Consent to Mainstream			PATIENT LABEL (if available)			
Cancer Genetic Testing						
Name of person to be tested				DOB		
Hospital				UR		
Sample to be collected Tumour Tissue (son			Blood (germline) Oth	er ()		
I consent to a genetic test for						
The gene(s)/gene panel being tested is						

Lunderstand that:

- 1. The meaning of the result is based on what is known now. This could change in the future.
- 2. There are limitations to genetic testing:
 - We do not know all the genes that cause cancers.
 - Genetic variants may be found that cannot be interpreted. These are called variants of unknown significance or VUS. A VUS cannot be used to guide clinical care.
- 3. Rarely, there may be a technical problem with a genetic test. Further sample(s) may be needed.
- 4. Test results may have implications for both my treatment/cancer risks AND for my family members.

I am aware that:

- 1. Samples will be stored after testing for at least the period required by laboratory guidelines.
- 2. I can change my mind about testing at any point before a report is issued.

I consent to the genetic testing described above. I have had the chance to ask questions and I am satisfied with the answers I have been given.						
I give permission for this genetic test result to be retained confidentially by the Adult Genetics Unit						
and/or given to health care services looking after other members of my family: Yes No						
Patient signature: Date:						
If I am unable to receive my genetic test result, I nominate the following individual(s) to receive it on my behalf:						
Name and Contact Information:						
Person obtaining consent: Signature:						
Position and specialty of person obtaining consent:						
Responsible Consultant (please print in capitals):						

OFFICIAL: Sensitive//Medical in confidence

This page is intentionally blank

PATHOLOGY REQUEST FORM

Genetic Testing (V1 Nov 2022)



AFFIX BARCODE HERE

PERSON BEING TESTED (all samples must include at least two patient identifiers)							
Family Name	Date of Birth	Sex	Ethnicity (if known)	Your Ref			
GivenName(s)	Medicare No.			Telephone			
Address: (Number, Street)	Suburb			Postcode			
Patient Status at the time of the service or when the specimen a private patient in a private hospital or approved day hospi a private patient in a private recognised hospital a public patient in a recognised hospital an outpatient public of in a recognised hospital	tal facility	Medicare Assignment "Section 20A of the Health Insurance Act 1973" I offer to assign my right to benefits to the approved pathology practitioner who will render the requested pathology service(s) and any eligible pathologist determinable services(s) established as necessary by the practitioner. Patient Signature & Date					
Your doctor has recommended that you use SA Pathology. You clinical grounds a Medicare rebate will only be payable if that p				pecified a particular pathologist on			
REQUESTING DOCTOR DETAILS	(COPY REPO	RTS TO				
Requesting Clinician:		Adult Genetic	s Unit				
in a quadamag a minaram		Royal Adelaid	de Hospital				
Responsible Consultant & provider numb	per:						
CLINICAL SETTING	<u> </u>						
★ Diagnostic test □ Predictive	test	× Affected					
☐ Carrier Test ☐ Prenatal	(please tick one)	☐ Unaffected (please tick one)					
TEST TYPE (please tick)							
☐ Common mutation screen X F	ull gene mutation ana	ılysis	☐ Known familial	mutation(s)			
CLINICAL NOTES							
This is a Medicare Funded Mainstream	Genetic Test						
Consent Obtained and Documented by ord		ES □NO					
MBS Criteria:							
☐ Breast Cancer with a Manchester so	core >15, or CanRisk	>10% (MBS i	tem number 73296	5)			
☐ Breast Cancer (HER2 negative) to c	letermine PARP inhib	itor Eligibility (MBS item number	73295)			
☐ Early-stage high risk brea	st cancer, OR	☐ Metastatic	breast cancer				
For Treatment Focused Genetic Testing, Result Required by:							
TESTS REQUESTED				EDTA BUCCAL SWAB OTHER			
TESTS REQUESTED							
4ml blood in EDTA tube for: 1. Genetic testing: Breast and Ovarian Cancer gene panel analysis (sequencing and del/dup studies)							
Doctor's Signature & Date							
I have verified FULL NAME, DOB and URN on the sample label and request form verbally with the patient and/or checking the patient's ID band.							
Collector's Signature:			d: / /				

OFFICIAL: Sensitive//Medical in confidence

This page is intentionally blank

Consumer Information Sheet Information about **Genetic Testing and Cancer**

This leaflet was written for people who are thinking about having a genetic test following a cancer diagnosis. This leaflet does not replace a discussion with your managing specialist. If you have any questions or concerns after reading this leaflet, please discuss them with your managing specialist or contact the Adult Genetics Unit.

What are genes?

The human body is made up of millions of cells. Each cell contains DNA. DNA spells out the genetic instructions (genes) the cells need. Some genes tell cells how to grow, divide and work properly. Some genes help keep DNA healthy. Other genes tell wornout cells when to self-destruct (die). These genes work together to control cell growth.

What is cancer?

The DNA in our cells is continually damaged by the things we are exposed to in our environment, for example UV light or cigarette smoke, and the process of aging. This DNA damage is usually repaired but the repair process is not perfect. This means that damage can build up in our DNA. If a cell has too much DNA damage it normally dies.

Cancer occurs when abnormal cells do not die and start to grow in an uncontrolled way. These abnormal cells can damage or invade the nearby tissues or spread to other parts of the body; this is called a cancer.

What is familial cancer?

Rarely, a person is born with a genetic error (called a variant or mutation) in a cell growth-control gene or a DNA-repair gene. These genetic errors increase the chance of developing a cancer. Usually, the genetic error has been inherited from the person's mother or father. If a genetic error is inherited, other blood relatives may also have an increased chance of developing cancer. This is called familial or hereditary cancer.

What is a genetic test?

A genetic test involves collecting a sample, usually blood. Genetic material (DNA) is extracted from the sample and analysed looking for genetic errors or variants.

- > Everyone's genes have differences or variants, this makes us each unique.
- Most genetic variants are harmless and do not cause problems.
- > Some genetic variants change how a gene works and **do** cause a problem, like an increased risk of developing a cancer.
- > The names for a variant that causes a medical problem include a disease-causing variant, mutation, genetic error or genetic fault.
- > Most genetic tests analyse a number of genes that are all known to cause a particular health problem, like an increased risk of cancer. This is called a gene panel test.
- Genetic testing is part of the standard care for patients with certain types of cancer. This genetic testing is not research based or part of a clinical trial.





Consumer Information Sheet

Why have a genetic test?

There are many reasons a doctor may suggest having a genetic test in the setting of a cancer diagnosis, including:

- > To help identify the best treatments for some types of cancer.
- > To understand the chance of developing another cancer.
- > To help family members understand their cancer risks.
- > To help family members manage and reduce their cancer risks through early cancer screening tests and other management options.

What are the possible outcomes of a genetic test?

- 1. No genetic variants are found. This is the most common result and is called a negative or uninformative test. This may mean that the cancer did not have an inherited genetic cause or that an inherited genetic cause cannot be found using the currently testing technology.
- 2. A genetic variant that explains the cancer is found. This is a less common result. This may influence cancer treatments. It also means that other family members may have the variant and can choose to have their own genetic test.
- 3. A variant that is not understood is found. This is an uncommon result and is called a variant of unknown significance or VUS. A VUS is neither good nor bad; its meaning is just not known yet. Sometimes more testing can help to understand the meaning of a VUS, or the meaning may become clearer overtime. A VUS cannot be used to influence cancer treatments or offer testing to other relatives.
- 4. An unexpected variant is found. This is a rare result called an incidental finding. It occurs when a genetic variant that causes a different medical problem is found.

What do I tell my family about genetic testing?

A genetic variant found in you may be relevant for your blood relatives. Genetic variants can occur in both sexes and both sexes can pass a genetic variant down to their children. Telling your family members about a genetic variant can be difficult but may help them understand and manage or reduce their cancer risks.

What about genetic tests and insurance?

A genetic test result is part of a person's health history. In Australia, premiums for private health insurance do **not** depend on health history. Previously, other types of insurance like income protection and life insurance could have been impacted by genetic testing. However, the laws have recently changed and there is now more protection from genetic discrimination by insurance companies. A genetic test should not impact insurance for a person with a cancer.

Where can I get more information or support?

> Watch Our Video (scan the QR code or use the link)

https://t2m.io/zr5HM4O0

> NSW Centre for Genetics Education

Inherited Cancers Australia

https://www.genetics.edu.au/ https://www.inheritedcancers.org.au/

> Adult Genetics Unit, Royal Adelaide Hospital

Tel: 08 7074 2697

The information contained within this leaflet does not constitute medical advice and is for general information only. Readers should always seek independent, professional advice where appropriate.



